10-KPeriod: FY2015

DEXCOM INC Annual Report, Year Ended Dec 31, 2015

Filed February 23, 2016For Securities:DXCM

Summary

DexCom Inc.'s 2016 10-K filing highlights its position as a leader in continuous glucose monitoring (CGM) systems for individuals with diabetes. The company has seen significant revenue growth, driven by its G4 PLATINUM and G5 Mobile systems, with increasing adoption of disposable sensors contributing to recurring revenue. DexCom is actively investing in research and development to enhance its product offerings and expand into new markets, including pediatric and in-hospital use. Despite strong revenue performance, DexCom continues to incur net losses, consistent with its early-stage growth phase and significant investment in innovation and market expansion. The company faces a competitive landscape but emphasizes its technological advancements, such as the G4 PLATINUM with Share and the G5 Mobile system, which offer enhanced connectivity and user convenience. Key to future success will be continued product innovation, regulatory approvals, market penetration, and securing favorable third-party reimbursement policies.

Financial Highlights

50 data points
Beta

Revenue

$400.70M

69.5% Gross Margin

Net Income

-$57.60M

-14.4% Net Margin

EPS (Diluted)

$-0.18

Total Assets

$292.00M

Cash & Equivalents

$86.10M

Free Cash Flow

$15.70M

Financial Statements
Beta
Revenue$400.70M
Cost of Revenue$123.60M
Gross Profit$278.40M
R&D Expenses$137.50M
SG&A Expenses$198.00M
Operating Expenses$335.50M
Operating Income-$57.10M
Interest Expense$400K
Net Income-$57.60M
EPS (Basic)$-0.18
Shares Outstanding (Basic)319.20M

Key Highlights

  • 1Significant revenue growth driven by the G4 PLATINUM and G5 Mobile continuous glucose monitoring (CGM) systems.
  • 2Expansion of product indications to include pediatric use, broadening the addressable market.
  • 3Introduction of "DexCom Share" technology, enabling remote monitoring of glucose data by designated followers.
  • 4Ongoing investment in research and development for next-generation CGM products and potential applications beyond glucose sensing.
  • 5Focus on increasing recurring revenue through disposable sensor sales.
  • 6Continued net losses, characteristic of a growth-stage medical device company investing heavily in R&D and market expansion.
  • 7Partnerships with insulin pump manufacturers (Animas, Tandem) to integrate CGM technology into insulin delivery systems.

Frequently Asked Questions

DexCom's primary products are continuous glucose monitoring (CGM) systems, including the G4 PLATINUM and G5 Mobile systems. These systems offer advantages over traditional finger-stick devices by providing real-time glucose readings, trend information, and alerts. They are designed for user convenience, improved glycemic control, and connectivity, allowing users to share their data with caregivers or 'followers'.

In the fiscal year ending December 31, 2015, DexCom reported significant product revenue growth, driven by increased sales volumes of its G4 PLATINUM and G5 Mobile systems, particularly disposable sensors. However, the company continued to incur net losses, reflecting substantial investments in research and development, sales, marketing, and manufacturing infrastructure necessary for growth and innovation.

DexCom faces several key risks, including intense competition from established medical device manufacturers, reliance on third-party payor reimbursement for product adoption, regulatory hurdles for new product approvals and expanded indications, manufacturing capacity challenges, potential supply chain disruptions, intellectual property protection, and the inherent risks associated with product liability claims. The company also notes the volatility of its stock price and the potential need for future funding.

DexCom's growth strategy includes establishing its technology platform as the leader in CGM, driving adoption through direct sales and marketing efforts, pursuing technology integration partnerships (especially with insulin pump companies), seeking broad reimbursement policies, leveraging cloud-based data platforms like CLARITY, and expanding product use to other patient demographics and settings. They are also exploring next-generation products and collaborations, such as with Verily Life Sciences.